Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note

Behavioural Brain Research

Volumn 222, Issue 1, 2011, Pages 33-42

  Klein, Alexander ^a   Gidyk, Darryl C ^a   Shriner, Alexandra M ^a   Colwell, Keri L ^a   Tatton, Nadine A ^a   Tatton, William G ^a   Metz, Gerlinde A ^a  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

Dopamine; Environmental toxins; Intracerebral; Parkinson's disease; Pesticide; Skilled movement

Indexed keywords

DOPAMINE; ROTENONE;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN DAMAGE; CONTROLLED STUDY; FEMALE; FOREBRAIN; MORPHOLOGY; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEMALE; FUNCTIONAL LATERALITY; INSECTICIDES; MEDIAL FOREBRAIN BUNDLE; MOVEMENT; MOVEMENT DISORDERS; NEURONS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, LONG-EVANS; ROTENONE; STEREOTYPED BEHAVIOR; TYROSINE 3-MONOOXYGENASE;

EID: 79953704795     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.03.018     Document Type: Article

References (62)

1. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968, 5:107-110.
2. Tatton W.G., Kwan M.M., Verrier M.C., Seniuk N.A., Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res 1990, 527:21-31.
3. Langston J.W., Irwin I., Langston E.B., Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984, 48:87-92.
4. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 2002, 3:574-579.
5. Iwaniuk A.N., Whishaw I.Q. On the origin of skilled forelimb movements. Trends Neurosci 2000, 23:372-376.
6. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
7. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005, 102:3413-3418.
8. Fleming S.M., Delville Y., Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behav Brain Res 2005, 156:201-213.
9. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002, 136:317-324.
10. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
11. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 2009, 34:279-290.
12. Lim M.L., Mercer L.D., Nagley P., Beart P.M. Rotenone and MPP+ preferentially redistribute apoptosis-inducing factor in apoptotic dopamine neurons. Neuroreport 2007, 18:307-312.
13. Meurers B.H., Zhu C., Fernagut P.O., Richter F., Hsia Y.C., Fleming S.M., et al. Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo. Neurobiol Dis 2009, 33:182-192.
14. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003, 23:10756-10764.
15. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003, 179:9-16.
16. Chen M.J., Yap Y.W., Choy M.S., Koh C.H., Seet S.J., Duan W., et al. Early induction of calpains in rotenone-mediated neuronal apoptosis. Neurosci Lett 2006, 397:69-73.
17. Phinney A.L., Andringa G., Bol J.G., Wolters E.C., van Muiswinkel F.L., van Dam A.M., et al. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat Disord 2006, 12:228-238.
18. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005, 280:34105-34112.
19. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997, 753:157-162.
20. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7:726-735.
21. Hoglinger G.U., Oertel W.H., Hirsch E.C. The rotenone model of parkinsonism - the five years inspection. J Neural Transm Suppl 2006, 269-272.
22. Lapointe N., St Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004, 18:717-719.
23. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22:404-420.
24. Ravenstijn P.G., Merlini M., Hameetman M., Murray T.K., Ward M.A., Lewis H., et al. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods 2008, 57:114-130.
25. Alam M., Mayerhofer A., Schmidt W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav Brain Res 2004, 151:117-124.
26. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 2002, 24:308-318.
27. Sindhu K.M., Saravanan K.S., Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005, 1051:25-34.
28. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
29. Paxinos G., Watson C. The rat brain in stereotactic coordinates 1997, Academic Press, San Diego, CA. 2nd ed.
30. Metz G.A., Whishaw I.Q. Skilled reaching an action pattern: stability in rat (Rattus norvegicus) grasping movements as a function of changing food pellet size. Behav Brain Res 2000, 116:111-122.
31. Whishaw I.Q., Pellis S.M. The structure of skilled forelimb reaching in the rat: a proximally driven movement with a single distal rotatory component. Behav Brain Res 1990, 41:49-59.
32. Metz G.A., Tse A., Ballermann M., Smith L.K., Fouad K. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis. Eur J Neurosci 2005, 22:735-744.
33. Metz G.A., Whishaw I.Q. Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination. J Neurosci Methods 2002, 115:169-179.
34. de Medinaceli L., Freed W.J., Wyatt R.J. An index of the functional condition of rat sciatic nerve based on measurements made from walking tracks. Exp Neurol 1982, 77:634-643.
35. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
36. Melvin N.R., Poda D., Sutherland R.J. A simple and efficient alternative to implementing systematic random sampling in stereological designs without a motorized microscope stage. J Microsc 2007, 228:103-106.
37. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991, 231:482-497.
38. Bjorklund A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr Opin Neurobiol 1992, 2:683-689.
39. Klein A., Metz G.A., Papazoglou A., Nikkhah G. Differential effects on forelimb grasping behavior induced by fetal dopaminergic grafts in hemiparkinsonian rats. Neurobiol Dis 2007, 27:24-35.
40. Smith L.K., Jadavji N.M., Colwell K.L., Katrina P.S., Metz G.A. Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur J Neurosci 2008, 27:2133-2146.
41. Klein A., Wessolleck J., Papazoglou A., Metz G.A., Nikkhah G. Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats. Behav Brain Res 2009, 199:317-325.
42. Gancher S., Mayer A., Youngman S. Changes in apomorphine pharmacodynamics following repeated treatment in 6-hydroxydopamine-lesioned rats. Brain Res 1996, 729:190-196.
43. Badiani A., Anagnostaras S.G., Robinson T.E. The development of sensitization to the psychomotor stimulant effects of amphetamine is enhanced in a novel environment. Psychopharmacology (Berl) 1995, 117:443-452.
44. Schmidt W.J., Lebsanft H., Heindl M., Gerlach M., Gruenblatt E., Riederer P., et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm 2008, 115:1385-1392.
45. Jadavji N.M., Kolb B., Metz G.A. Enriched environment improves motor function in intact and unilateral dopamine-depleted rats. Neuroscience 2006, 140:1127-1138.
46. Rojas J.C., Simola N., Kermath B.A., Kane J.R., Schallert T., Gonzalez-Lima F. Striatal neuroprotection with methylene blue. Neuroscience 2009, 163:877-889.
47. Hirsch E.C., Hoglinger G., Rousselet E., Breidert T., Parain K., Feger J., et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl 2003, 89-100.
48. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., et al. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 2004, 478:418-426.
49. DeVries A.C., Nelson R.J., Traystman R.J., Hurn P.D. Cognitive and behavioral assessment in experimental stroke research: will it prove useful?. Neurosci Biobehav Rev 2001, 25:325-342.
50. Knieling M., Metz G.A., Antonow-Schlorke I., Witte O.W. Enriched environment promotes efficiency of compensatory movements after cerebral ischemia in rats. Neuroscience 2009, 163:759-769.
51. Metz G.A., Antonow-Schlorke I., Witte O.W. Motor improvements after focal cortical ischemia in adult rats are mediated by compensatory mechanisms. Behav Brain Res 2005, 162:71-82.
52. Weiss L.R., Orzel R.A. Some comparative toxicologic and pharmacologic effects of dimethyl sulfoxide as a pesticide solvent. Toxicol Appl Pharmacol 1967, 11:546-557.
53. Wood D.C., Wood J. Pharmacologic and biochemical considerations of dimethyl sulfoxide. Ann N Y Acad Sci 1975, 243:7-19.
54. Authier N., Dupuis E., Kwasiborski A., Eschalier A., Coudore F. Behavioural assessment of dimethylsulfoxide neurotoxicity in rats. Toxicol Lett 2002, 132:117-121.
55. Castro C.A., Hogan J.B., Benson K.A., Shehata C.W., Landauer M.R. Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80, and emulphor-620. Pharmacol Biochem Behav 1995, 50:521-526.
56. Garcia-Garcia F., Ponce S., Brown R., Cussen V., Krueger J.M. Sleep disturbances in the rotenone animal model of Parkinson disease. Brain Res 2005, 1042:160-168.
57. Hanslick J.L., Lau K., Noguchi K.K., Olney J.W., Zorumski C.F., Mennerick S., et al. Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system. Neurobiol Dis 2008.
58. Matheus M.G., de Lacerda J.C., Guimaraes F.S. Behavioral effects of " vehicle" microinjected into the dorsal periaqueductal grey of rats tested in the elevated plus maze. Braz J Med Biol Res 1997, 30:61-64.
59. Qi W., Ding D., Salvi R.J. Cytotoxic effects of dimethyl sulphoxide (DMSO) on cochlear organotypic cultures. Hear Res 2008, 236:52-60.
60. Ren Y., Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem 2007, 103:303-311.
61. Schmidt W.J., Alam M. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J Neural Transm Suppl 2006, 273-276.
62. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 1985, 62:389-394.